Draft guidance in the UK has provisionally recommended that digital cognitive behavioural therapy (CBT) apps can be used within the NHS to treat children and young people with mild to moder
German specialty drugmaker Neuraxpharm has licensed commercial rights in Europe to a wearable device developed by Spanish start-up mjn-neuro that is designed to warn a person with epilepsy
Young adults with depression have been treated effectively with a cognitive behavioural therapy (CBT) course – delivered via text message – in a pilot study conducted by researchers in the
Hard on the heels of the official launch of its digital disease management platform, Aptar Pharma has secured a partnership with Italian drugmaker Chiesi to deploy it in support of patients
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.